Veracyte (VCYT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Veracyte (VCYT)
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Key Insights
Critical company metrics and information
Share Price
$44.13Market Cap
$3.42 BillionTotal Outstanding Shares
77.50 Million SharesTotal Employees
815Dividend
No dividendIPO Date
October 30, 2013SIC Description
Services-medical LaboratoriesHomepage
https://www.veracyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $71.55 Million |
Net Cash Flow From Financing Activities, Continuing | $10.06 Million |
Net Cash Flow From Financing Activities | $10.06 Million |
Exchange Gains/Losses | $274000.00 |
Net Cash Flow From Investing Activities | $-4.63 Million |
Net Cash Flow From Investing Activities, Continuing | $-4.63 Million |
Net Cash Flow From Operating Activities, Continuing | $66.12 Million |
Net Cash Flow From Operating Activities | $66.12 Million |
Net Cash Flow | $71.83 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Preferred Stock Dividends And Other Adjustments | $0.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Earnings Per Share | $0.13 |
Operating Expenses | $439.09 Million |
Diluted Earnings Per Share | $0.13 |
Net Income/Loss Attributable To Parent | $-9.27 Million |
Benefits Costs and Expenses | $433.50 Million |
Other Operating Expenses | $370.41 Million |
Basic Average Shares | $76.26 Million |
Research and Development | $68.68 Million |
Operating Income/Loss | $-23.54 Million |
Diluted Average Shares | $77.50 Million |
Income Tax Expense/Benefit | $1.10 Million |
Income/Loss From Continuing Operations After Tax | $-9.27 Million |
Revenues | $425.33 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-9.27 Million |
Net Income/Loss | $-9.27 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Costs And Expenses | $439.09 Million |
Income/Loss From Continuing Operations Before Tax | $-8.17 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities And Equity | $1.28 Billion |
Other Current Liabilities | $29.90 Million |
Equity Attributable To Parent | $1.18 Billion |
Current Liabilities | $70.31 Million |
Noncurrent Assets | $918.17 Million |
Current Assets | $356.85 Million |
Other Non-current Assets | $809.29 Million |
Noncurrent Liabilities | $28.67 Million |
Equity | $1.18 Billion |
Intangible Assets | $108.87 Million |
Assets | $1.28 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Wages | $30.74 Million |
Accounts Payable | $9.67 Million |
Inventory | $20.36 Million |
Other Current Assets | $336.49 Million |
Liabilities | $98.98 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Veracyte (VCYT)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.